David Szwajcer

Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Oncology · 2015 · 363 citations

Medicine, Hematology, Immunology +17

The 4-pregnene and 5alpha-pregnane progesterone metabolites formed in nontumorous and tumorous breast tissue have opposite effects on breast cell proliferation and adhesion.

John P. Wiebe, David Muzia, Jennifer J. Hu et al. · PubMed · 2000 · 114 citations

Medicine, Biochemistry, Oncology +8

Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial

Antonio Uccelli, Alice Laroni, Rehiana Ali et al. · The Lancet Neurology · 2021 · 109 citations

Life Sciences, Neurology, Neuroscience +15

Impact of pre‐transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation

Areej El‐Jawahri, Yi‐Bin Chen, Ruta Brazauskas et al. · Cancer · 2017 · 100 citations · Full text

Medicine, Hematology, Outcomes Research +13

Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial

Irwin Walker, Tony Panzarella, Stephen Couban et al. · The Lancet Haematology · 2020 · 96 citations

Life Sciences, Hematology, Immunology +12